Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 1

Status

Completed 2Recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Simpson-Golabi-Behmel syndrome 1Recurrence 1Hepatoblastoma 1Carcinoma, Hepatocellular 1Advanced or Metastatic HCC 1

Interventions

Cyclophosphamide 626pembrolizumab 505Paclitaxel 456Gemcitabine 439Carboplatin 437Cisplatin 420Radiotherapy 382fludarabine 367Nivolumab 340Docetaxel 278Bevacizumab 276Irinotecan 258Magnetic Resonance Spectroscopy 245Fluorouracil 229Dexamethasone 225Specimen Handling 223Capecitabine 218Rituximab 206Oxaliplatin 201Cytarabine 201Ipilimumab 198Temozolomide 197Biopsy 197fludarabine phosphate 194Etoposide 181Lenalidomide 176Doxorubicin 175Leucovorin 174Cetuximab 171Injections 170

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × codrituzumab × Clear all
NCT04928677 2026-02-17

A Study of Codrituzumab in Children and Young Adults With Solid Tumors and Have Not Responded to Treatment or Have Come Back After Treatment

Memorial Sloan Kettering Cancer Center

Phase 1 Recruiting
50 enrolled
Gastrointestinal

Simpson-Golabi-Behmel syndrome, Recurrence, Hepatoblastoma

NCT00976170 2014-10-03

Study of GC33 and Sorafenib in Combination in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma)

Chugai Pharmaceutical

Phase 1 Completed
42 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT00746317 2012-10-17

A Phase I Study of GC33 in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma)

Chugai Pharmaceutical

Phase 1 Completed
27 enrolled

Advanced or Metastatic HCC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡